Naturex granted Fraxinus-based patent to combat metabolic syndrome by improving blood sugar regulation

11/27/2012

South Hackensack, NJ – November 27th - Naturex announces the approval of U.S. Patent Number: 8,293,292 “Extract of Fraxinus Excelsior seeds and therapeutic applications therefor”.

 

Naturex has developed FraxiPure®, an innovative extract of Fraxinus with scientifically-documented properties supporting its use to fight the metabolic syndrome. Metabolic syndrome is a combination of medical disorders that increase the risk of developing cardiovascular diseases and diabetes. According to the World Health Organization, 347 million people worldwide have diabetes[1].  It also predicts that deaths associated with diabetes will increase by two thirds between 2008 and 2030. In the US, 7% of the population is affected by diabetes and it cost the United States an estimated $132 billion in 2002 in medical expenditures[2].

Fraxinus excelsior is a tree in the Oleaceae family and is more commonly known as “common ash” or “European ash” in the countries of temperate Asia and Europe. This tree is also widely distributed throughout the south-eastern region of Morocco where Naturex operates a large extraction facility.

Naturex proprietary studies demonstrated that Fraxinus excelsior seed extract exhibited potent anti-hyperglycemic activities. The US patent application, published as US8293292B2, covers the glycemia regulation activity of FraxiPure® as well as the extraction and characterization of new secoiridoid compounds[3]. The Naturex team of research scientists discovered these new components by using highly sophisticated analytical methods, including nuclear magnetic resonance (NMR) and mass spectroscopy (MS).

Marc Roller, Scientific Director, declared “Our patent describes a unique extraction and isolation process to obtain an extract mainly standardized to two novel compounds: nuzhenide and GI3. It also discloses the significant effect of FraxiPure® to control glycemia levels in people suffering from metabolic syndrome. People with metabolic syndrome have an increased long-term risk for developing type 2 diabetes.”

FraxiPure® is already included as an ingredient in dietary supplements marketed in the USA and EU. It can be formulated into capsules, tablets, softgels as well as functional ingredients and comes as a powder. This innovative ingredient is a promising natural solution to maintain healthy blood glucose levels. Further scientific studies are ongoing and people diagnosed with metabolic syndrome or diabetes, or who suspect they may have one of these diseases, should seek professional guidance from their health practitioner.

 

About Naturex: 

Naturex manufactures natural speciality ingredients for the Food & Beverage, Nutrition & Health and Personal Care industries. Headquartered in France, Naturex employs 1300 people and has 15 production units located in Europe (France, Italy, Spain, Switzerland, England and Poland), the United States (New Jersey and California), Brazil, Australia, Morocco and India. In addition, the group has several sales offices worldwide. www.naturex.com

Your contacts at Naturex:

Antoine Dauby
 Group Marketing Director
 Tel: +334 90 23 96 89
 a.dauby@naturex.com  

 

Karine Morel
 Communication Manager
 Tel: +334 90 23 96 89
 k.morel@naturex.com

[1] http://www.who.int/mediacentre/factsheets/fs312/en/

[2] Hogan et al, 2003, Diabetes Care, 26, 917-32

[3] Fraxinus excelsior contains primarily coumarins, secoiridoids, and phenylethanoids.

actu_143_Fichierpdf.pdf
 
of 225
BACK